Abstract
The goal of each antiemetic therapy is to prevent chemotherapy-induced nausea and vomiting (CINV).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Coates A, Abraham S, Kaye SB, et al. On the receiving end – patient perception of the sideeffects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19:203-208.
Griffin AM, Butow PN, Coates AS, et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996;7:189-195.
Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol. 2007;61:162-175.
Aapro MS. Review of experience with ondansetron and granisetron. Ann Oncol. 1993; 4(suppl 3):9-14.
Hesketh PJ, Grunberg S, Gralla R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomised, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112-4119.
Gralla RJ. Current issues in the management of nausea and vomiting. Ann Oncol. 1993;4(suppl 3):3-7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2013 Springer Healthcare
About this chapter
Cite this chapter
Aapro, M., Jordan, K., Feyer, P. (2013). Introduction. In: Prevention of Nausea and Vomiting in Cancer Patients. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-58-0_1
Download citation
DOI: https://doi.org/10.1007/978-1-907673-58-0_1
Published:
Publisher Name: Springer Healthcare, Tarporley
Print ISBN: 978-1-908517-87-6
Online ISBN: 978-1-907673-58-0
eBook Packages: MedicineMedicine (R0)